Jecko Thachil: Interrupting Antiplatelet Therapy for Urgent and Planned Surgery
Jecko Thachil, MAHSC Professor, at the University of Manchester, shared a post on LinkedIn about a recent article he and his colleagues co-authored, adding:
“Cardiovascular and cerebrovascular diseases are major causes of morbidity and morality in the world. Antiplatetelet therapies play a major role in the management of these conditions.
But when a patient receiving antiplatelet medications requires urgent or planned surgery, how do we deal with interrupting these treatments? Discussed in the following review.”
Title: How to undertake procedures while on antiplatelet agents: a hematologist’s view
Authors: Dawn Swan, Robert Turner, James Douketis, Jecko Thachil
Read the Full Article on RPTH.
Stay updated on all scientific advances with Hemostasis Today.
-
Mar 4, 2026, 08:40Wolfgang Miesbach։ Highlighting the Social and Psychological Impact of Factor VII Deficiency
-
Mar 3, 2026, 17:12Matteo Foschi: Cancer Worsens Prognosis after Breakthrough Ischemic Stroke Despite Oral Anticoagulation
-
Mar 3, 2026, 17:04Shiny K Kajal: Therapeutic Apheresis Is Redefining the Clinical Scope of Transfusion Medicine
-
Mar 3, 2026, 16:58Non-Carrier Mothers of Inv22 Hemophilia A Patients Frequently Harbor Additional F8 Gene Rearrangements – JTH
-
Mar 3, 2026, 16:53Valentina Rossi: Addressing Inflammation and Immune Mechanisms in Cardiomyopathy Management
-
Mar 3, 2026, 16:45Emmanuel J Favaloro: New Publication on Artificial Intelligence in Thrombosis and Hemostasis in CCLM
-
Mar 3, 2026, 16:32Scott E. Smith: Why Hematology Research Is the True Leader of all Medical Disciplines
-
Mar 3, 2026, 16:21Tareq Abadl: Why HIV Antibodies Stay Positive Even When Viral Load Is Zero?
-
Mar 3, 2026, 16:12Mark Crowther Congratulates Mary Cushman on Her Appointment as ISTH President